European Union - English - EMA (European Medicines Agency)

stada arzneimittel ag - teriparatide - osteoporosis - calcium homeostasis - movymia is indicated in adults.treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture. in postmenopausal women, a significant reduction in the incidence of vertebral and non vertebral fractures but not hip fractures has been demonstrated.treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture.

European Union - English - EMA (European Medicines Agency)

gedeon richter plc. - teriparatide - osteoporosis - calcium homeostasis - terrosa is indicated in adults.treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture. in postmenopausal women, a significant reduction in the incidence of vertebral and non vertebral fractures but not hip fractures has been demonstrated.treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture.

European Union - English - EMA (European Medicines Agency)

eurogenerics holdings b.v. - teriparatide - osteoporosis - calcium homeostasis - qutavina is indicated in adults.treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture. in postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures have been demonstrated.treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture.

European Union - English - EMA (European Medicines Agency)

theramex ireland limited - teriparatide - osteoporosis - calcium homeostasis - livogiva is indicated in adults.treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture. in postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures have been demonstrated.treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture.

European Union - English - EMA (European Medicines Agency)

accord healthcare s.l.u. - teriparatide - osteoporosis - calcium homeostasis - sondelbay is indicated in adults.treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture. in postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures have been demonstrated.treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture.

European Union - English - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - teriparatide - osteoporosis; osteoporosis, postmenopausal - calcium homeostasis - teriparatide sun is indicated in adults.treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture (see section 5.1). in postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures has been demonstrated.treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture (see section 5.1).

European Union - English - EMA (European Medicines Agency)

strides pharma (cyprus) limited - teriparatide - osteoporosis; osteoporosis, postmenopausal - calcium homeostasis - kauliv is indicated in adults. treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture (see section 5.1). in postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures has been demonstrated. treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture (see section 5.1).,

Israel - English - Ministry of Health

eli lilly israel ltd, israel - teriparatide - solution for injection - teriparatide 250 mcg/ml - teriparatide - teriparatide - treatment of postmenopausal women with osteoporosis at high risk for fracture:forteo is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy. in postmenopausal women with osteoporosis, forteo increases bmd reduces the risk of vertebral and nonvertebral fractures . increase of bone mass in men with primary or hypogonadal osteoporosis at high risk for fracture :forteo is indicated to increase bone mass in men with primary or hypogonadal osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy . treatment of men and women with glucocorticoid-induced osteoporosis at high risk for fracture:forteo is indicated for the treatment of men and women with osteoporosis associated with sustained systemic glucocorticoid therapy (daily dosage equivalent to 5 mg or greater of prednisone) at high risk for fracture, defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy .

Singapore - English - HSA (Health Sciences Authority)

dksh singapore pte. ltd. - teriparatide (rdna origin) - injection, solution - 750 mcg/3 ml - teriparatide (rdna origin) 750 mcg/3 ml

European Union - English - EMA (European Medicines Agency)

eli lilly nederland b.v. - teriparatide - osteoporosis; osteoporosis, postmenopausal - calcium homeostasis - treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture. in postmenopausal women, a significant reduction in the incidence of vertebral and nonvertebral fractures but not hip fractures has been demonstrated.treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture.